Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson’s disease
This trial is the largest to date to study the effect of ambroxol in PD, utilise a genetically stratified PD population and will provide robust estimates of the efficacy of ambroxol in slowing PD clinical progression.
Authors
- Joy Duffen (ORCID: https://orcid.org/0000-0002-0149-6656)
- Marco Toffoli (ORCID: https://orcid.org/0000-0002-3255-9648)
- Nick Freemantle (ORCID: https://orcid.org/0000-0001-5807-5740)
- David Trevor Dexter (ORCID: https://orcid.org/0000-0002-7974-9588)
- Felicia Ikeji
- Elisa Menozzi (ORCID: https://orcid.org/0000-0003-3565-7910)
- Helen Matthews
- Paul M. Watts
- Moss Jp
- Mairead Cullen
- Tom Foltynie (ORCID: https://orcid.org/0000-0003-0752-1813)
- Richard K. Wyse
- Anthony H. V. Schapira
- Werner Poewe
- Olivier Rascol
- Saiam Ahmed
- Kashfia Chowdhury
Institutions
- Innsbruck Medical University (AT)
- Inserm (FR)
- Queen Mary University of London (GB)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- The Royal Free Hospital (GB)
- University of Rochester Medical Center (US)
- MRC Clinical Trials Unit at UCL (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Research Network (United States) (US)
- Cure Parkinson's Trust (GB)
- Comprehensive Clinical Trials (US)
- University College London (GB)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1007/s00415-026-13683-7
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Van Andel Research Institute
- Parkinson's UK